骨疏康胶囊联合骨化三醇和阿仑膦酸钠治疗骨质疏松的临床研究

目的观察骨疏康胶囊联合骨化三醇和阿仑膦酸钠治疗骨质疏松的临床疗效。方法选取西安交通大学医学院附属红会医院2015年1月—2015年10月就诊的骨质疏松症患者106例,随机分为对照组和治疗组,每组各53例。对照组患者口服骨化三醇胶丸,0.25μg/次,1次/d,阿仑膦酸钠片70 mg/次,1次/周,治疗组在对照组的基础上口服骨疏康胶囊,4粒/次,2次/d。两组均连续治疗6个月。观察两组的临床疗效,同时比较治疗前后两组患者的骨密度(BMD)、骨钙素、血清钙和碱性磷酸酶。结果对照组和治疗组的临床总有效率为79.25%和88.68%,两组比较差异具有统计学意义(P0.05)。治疗后两组腰椎2-4(L2~4)、股骨颈、股骨大转子的BMD均较治疗前显著升高,差异具有统计学意义(P0.05);且治疗组治疗后L2~4、股骨颈、股骨大转子的BMD均显著大于对照组,两组比较差异具有统计学意义(P0.05)。两组骨钙素和血清钙均较治疗前显著升高,碱性磷酸酶较治疗前显著降低,同组治疗前后差异有统计学意义(P0.05);且治疗组的变化更显著,两组比较差异有统计学意义(P0.05)。结论骨疏康胶囊联合骨化三醇和阿仑膦酸钠治疗骨质疏松临床疗效确切,可明显改善骨密度等指标,安全性高,具有一定的临床推广应用价值。

Clinical study on Gushukang Capsules combined with calcitriol and alendronate sodium in treatment of osteoporosis

Objective To observe the clinical effect of Gushukang Capsules combined with calcitriol and alendronate sodium in treatment of osteoporosis. Methods Patients (106 cases) with osteoporosis in Honghui Hospital Affiliated to Xi’an Jiaotong University Medical College from January 2015 to October 2015 were randomly divided into control and treatment groups, and each group had 53 cases. Patients in the control group were po administered with Calcitriol Soft Capsules, 0.25μg/time, once daily;And they were also po administered with Alendronate Sodium Tablets, 70 mg/time, weekly. The patients in the treatment group were po administered with Gushukang Capsules on the basis of the control group, 4 grains/time, twice daily. The patients in two groups were treated for 6 months. After treatment, the clinical efficacy was evaluated, and the changes of BMD, osteocalcin, serum calcium, and alkaline phosphatase in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 79.25%and 88.68%, respectively, and there were differences between two groups (P<0.05). After treatment, BMD of L2~4, femoral neck, and large femoral rotor were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). After treatment, osteocalcin and serum calcium in two groups were obviously increased, but alkaline phosphatase was decreased, and there were differences in the same group (P<0.05). And the changes of these observational indexes in the treatment group were more obvious, with significant difference between two groups (P<0.05). Conclusion Gushukang Capsules combined with calcitriol and alendronate sodium has an exact clinical efficacy in treatment of osteoporosis, can obviously improve the bone density with high safety, which has a certain clinical application value.